Dry Eye Disease (DED) - Market Insights, Epidemiology and Market Forecast to 2028

‘Dry Eye Disease (DED) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of DED in EU5 (Germany, Spain, Italy, France and United Kingdom).

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Dry Eye Disease (DED) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Dry Eye Disease (DED) - Disease Understanding and Treatment Algorithm
The Dry Eye Disease (DED) market report gives the thorough understanding of the Dry Eye Disease by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Dry Eye Disease in Europe.

Dry Eye Disease Epidemiology
The Dry Eye Disease (DED) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 5 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, diagnosed cases, gender-specific prevalent cases, severity-specific prevalent cases, type-specific prevalent cases and age-specific prevalent cases) scenario of Dry Eye Disease (DED) in the 7MM covering EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2017-2028.

According to the author, the total number of prevalent cases of Dry Eye Disease (DED) in 7 MM was found to be 11,939,169, in the year 2017.

Dry Eye Disease Drug Chapters
This segment of the Dry Eye Disease report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

There are many over the counter therapies such as “artificial tears”, ocular surface lubricants that have been used since a very long time to treat DED. These therapies have been included in the forecast model since it focuses both on the prescription therapies as well as OTC products such as Hyaluronic acid, Polyvinyl alcohol, Sodium chloride, Hypromellose, Poly(1-vinyl-2-pyrrolidon), Povidone, Carboxymethylcellulose, Ketorolac tromethamine, Hypromellose and many others that are being used to treat DED. Some of the major products belonging to this category are Novatears/Evotears (Novaliq/Ursapharm), Genteal/Systane/Tears Naturale (Alcon/Novartis), Refresh/Optive (Allergan), Soothe (Bausch & Lomb/Valeant, Visu XL/Xailin Hydrate/Xailin Gel (Visufarma) and many others. Detailed chapter for upcoming therapies like Visomitin, RGN-259 and many others have been covered in the report.

Dry Eye Disease Market Outlook
The Dry Eye Disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the author, the market of Dry Eye Disease in 5MM was found to be USD 602.62 million in 2017, and is expected to increase from 2017-2028.

Dry Eye Disease Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Dry Eye Disease Report Insights

Patient Population
Therapeutic Approaches
Pipeline Analysis
Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Dry Eye Disease Report Key Strengths

10 Year Forecast
5MM Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition

Dry Eye Disease Report Assessment

Current Treatment Practices
Unmet Needs
Detailed Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving Dry Eye Disease market
Organize sales and marketing efforts by identifying the best opportunities for Dry Eye Disease market
To understand the future market competition in the Dry Eye Disease market.

1. Key Insights

2. Dry Eye Disease Market Overview at a Glance

2.1. Market Share (%) Distribution of Dry Eye Disease in 2017
2.2. Market Share (%) Distribution of Dry Eye Disease in 2028

3. Disease Background and Overview

3.1. Introduction
3.2. Historical overview of dry eye
3.3. Classification schemes for dry eye disease
3.4. Etiology and risk factors
3.5. Causes
3.6. Signs and Symptoms
3.7. Pathology of Dry Eye Disease
3.8. Diagnosis

4. Epidemiology and Patient Population – EU5 Markets

4.1. Key Findings
4.2. KOL’s Views: Epidemiology
4.3. EU5 Total Prevalent Patient Population of Dry Eye Disease

5. Country Wise-Epidemiology of Dry Eye Disease

5.1. EU5
5.1.1. Assumptions and Rationale
5.1.2. Germany
5.1.3. France
5.1.4. Italy
5.1.5. Spain
5.1.6. The United Kingdom

6. Treatment and Management of Dry Eye Disease7. Unmet Needs

8. Marketed Drugs

8.1. IKERVIS: Santen Pharmaceutical
8.1.1. Product Description
8.1.2. Regulatory Milestones
8.1.3. Safety and Efficacy
8.1.4. Product Profile

9. Emerging Therapies

9.1. Visomitin: Mitotech pharma
9.1.1. Product Description
9.1.2. Other development Activities
9.1.3. Clinical Development
9.1.4. Safety and Efficacy
9.1.5. Advantages and Disadvantages
9.1.6. Product Profile
9.2. RGN-259: ReGen Tree
9.2.1. Product Description
9.2.2. Other development Activities
9.2.3. Clinical Development
9.2.4. Safety and Efficacy
9.2.5. Advantages and Disadvantages
9.2.6. Product Profile
9.3. HL036: HanAll BioPharma
9.3.1. Product Description
9.3.2. Other development Activities
9.3.3. Clinical Development
9.3.4. Safety and Efficacy
9.3.5. Advantages and Disadvantages
9.3.6. Product Profile
9.4. Tavilermide ophthalmic solution: Mimetogen Pharmaceuticals
9.4.1. Product Description
9.4.2. Other development Activities
9.4.3. Clinical Development
9.4.4. Safety and Efficacy
9.4.5. Advantages and Disadvantages
9.4.6. Product Profile
9.5. OCU310: Ocugen
9.5.1. Product Description
9.5.2. Other development Activities
9.5.3. Clinical Development
9.5.4. Safety and Efficacy
9.5.5. Advantages and Disadvantages
9.5.6. Product Profile
9.6. KPI-121: Kala Pharmaceuticals
9.6.1. Product Description
9.6.2. Other development Activities
9.6.3. Clinical Development
9.6.4. Safety and Efficacy
9.6.5. Advantages and Disadvantages
9.6.6. Product Profile
9.7. CyclASol: Novaliq
9.7.1. Product Description
9.7.2. Other Development Activities
9.7.3. Clinical Development
9.7.4. Safety and Efficacy
9.7.5. Advantages and Disadvantages
9.7.6. Product Profile
9.8. CEQUA: Sun Pharma
9.8.1. Product Description
9.8.2. Clinical Development
9.8.3. Safety and Efficacy
9.8.4. Advantages and Disadvantages
9.8.5. Product Profile
9.9. Tivanisiran: Sylentis, S.A.
9.9.1. Product Description
9.9.2. Other Development Activity
9.9.3. Clinical Development
9.9.4. Safety and Efficacy
9.9.5. Advantages and Disadvantages
9.9.6. Product Profile
9.10. Reproxalap: Aldeyra Therapeutics
9.10.1. Product Description
9.10.2. Clinical Development
9.10.3. Safety and Efficacy
9.10.4. Advantages and Disadvantages
9.10.5. Product Profile
9.11. Xiidra: Novartis
9.11.1. Product Description
9.11.2. Other Development Activity
9.11.3. Clinical Development
9.11.4. Safety and Efficacy
9.11.5. Advantages and Disadvantages
9.11.6. Product Profile

10. Dry Eye Disease: EU-5 Market Analysis

10.1. Key Findings
10.2. KOL’s Views: Treatment & Diagnosis
10.3. Market Size of Dry Eye Disease in EU5
10.4. Market Size of Dry Eye Disease by Therapies
10.5. Market size of Dry Eye Disease by Types

11. Market Outlook by Country

11.1. EU-5 Countries: Market Outlook
11.2. Germany
11.2.1. Total Market size of Dry Eye Disease
11.2.2. Market Size of Dry Eye Disease by Therapies
11.2.3. Total Market size of Dry Eye Disease by Types
11.3. France
11.3.1. Total Market size of Dry Eye Disease
11.3.2. Market Size of Dry Eye Disease by Therapies
11.3.3. Total Market size of Dry Eye Disease by Types
11.4. Italy
11.4.1. Total Market size of Dry Eye Disease
11.4.2. Market Size of Dry Eye Disease by Therapies
11.4.3. Total Market size of Dry Eye Disease by Types
11.5. Spain
11.5.1. Total Market size of Dry Eye Disease
11.5.2. Market Size of Dry Eye Disease by Therapies
11.5.3. Total Market size of Dry Eye Disease by Types
11.6. United Kingdom
11.6.1. Total Market size of Dry Eye Disease
11.6.2. Market Size of Dry Eye Disease by Therapies
11.6.3. Total Market size of Dry Eye Disease by Types

12. Market Drivers13. Market Barriers

14. Appendix

14.1. Report Methodology

15. Capabilities16. Disclaimer17. About the Author

List of Tables

Table 1 Prevalent Population of Dry Eye Disease in the 7MM (2017–2028)
Table 2 Total Adult Cases of Dry Eye Disease in the 7MM (2017–2028)
Table 3 Age-specific Prevalent Cases of Dry Eye Disease in the United States (2017–2028)
Table 4 Prevalence of DED in Adults in the United States (2017–2028)
Table 5 Gender-specific Prevalence of Dry Eye Disease in the United States (2017–2028)
Table 6 Severity-specific Prevalent Cases of Dry Eye Disease in the United States (2017–2028)
Table 7 Prevalence of Clinical Manifestation of DED in Adults in the United States (2017–2028)
Table 8 Diagnosed Cases of Dry Eye Disease in the United States (2017–2028)
Table 9 Prevalence of Dry Eye Disease in Germany by Age-group (2017–2028)
Table 10 Total Prevalence of Dry Eye Disease in Adults in Germany (2017–2028)
Table 11 Gender-specific Prevalence of Dry Eye Disease in Adults in Germany (2017–2028)
Table 12 Severity-specific prevalent cases of Dry Eye Disease in Germany (2017–2028)
Table 13 Prevalence of Clinical Manifestation of DED in Adults in Germany (2017–2028)
Table 14 Diagnosed Cases of Dry Eye Disease in Germany (2017–2028)
Table 15 Age-specific Prevalence of Dry Eye Disease in France (2017–2028)
Table 16 Total Prevalence of Dry Eye Disease in France (2017–2028)
Table 17 Gender-specific Prevalent Cases of Dry Eye Disease in France (2017–2028)
Table 18 Severity Specific Prevalence of Dry Eye Disease in France (2017–2028)
Table 19 Prevalence of Clinical Manifestation of DED in Adults in France (2017–2028)
Table 20 Diagnosed Cases of Dry Eye Disease in France (2017–2028)
Table 21 Prevalent Cases of Dry Eye Disease By Age-group in Italy (2017–2028)
Table 22 Total Prevalence of Dry Eye Disease in Adults in Italy (2017–2028)
Table 23 Gender-specific Prevalence of Dry Eye Disease in Italy (2017–2028)
Table 24 Severity-specific Prevalent Cases of Dry Eye Disease in Italy (2017–2028)
Table 25 Prevalence of Clinical Manifestation of DED in Adults in Italy (2017–2028)
Table 26 Diagnosed Cases of Dry Eye Disease in Italy (2017–2028)
Table 27 Prevalent Cases of Dry Eye Disease by Age-group in Spain (2017–2028)
Table 28 Total Prevalence of Dry Eye Disease in Adults in Spain (2017–2028)
Table 29 Gender-specific Prevalence of Dry Eye Disease in Spain (2017–2028)
Table 30 Severity-specific Prevalent Cases of Dry Eye Disease in Spain (2017–2028)
Table 31 Prevalence of Clinical Manifestation of DED in Adults in Spain (2017–2028)
Table 32 Diagnosed Cases of Dry Eye Disease in Spain (2017–2028)
Table 33 Prevalent Cases of Dry Eye Disease by Age-group in the United Kingdom (2017–2028)
Table 34 Total Prevalence of Dry Eye Disease in Adults the United Kingdom (2017–2028)
Table 35 Gender-specific Prevalence of DED in the United Kingdom (2017–2028)
Table 36 Severity-specific Prevalent Cases of Dry Eye Disease in the UK (2017–2028)
Table 37 Prevalence of Clinical Manifestation of DED in Adults in the UK (2017–2028)
Table 38 Diagnosed Cases of Dry Eye Disease in the United Kingdom(2017–2028)
Table 39 Age-Group Specific Prevalence of Dry Eye Disease in Japan (2017–2028)
Table 40 Total Prevalence of Dry Eye Disease in Adults Japan (2017–2028)
Table 41 Gender-specific Prevalence of Dry Eye Disease in Japan (2017–2028)
Table 42 Severity-specific Prevalent Cases of Dry Eye Disease in Japan (2017–2028)
Table 43 Prevalence of Clinical Manifestation of DED in Adults in Japan (2017–2028)
Table 44 Diagnosed Cases of Dry Eye Disease in Japan (2017–2028)
Table 45 Provigil, Clinical Trial Description, 2019
Table 46 Solriamfetol, Clinical Trial Description, 2019
Table 47 Key cross competition- Emerging Therapies
Table 48 7 Major Market Size of Dry Eye Disease in USD Million (2017–2028)
Table 49 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017–2028)
Table 50 United States Market Size of Dry Eye Disease in USD Million (2017–2028)
Table 51 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017–2028)
Table 52 Germany Market Size of Dry Eye Disease in USD Million (2017–2028)
Table 53 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017–2028)
Table 54 France Market Size of Dry Eye Disease in USD Million (2017–2028)
Table 55 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017–2028)
Table 56 Italy Market Size of Dry Eye Disease in USD Million (2017–2028)
Table 57 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017–2028)
Table 58 Spain Market Size of Dry Eye Disease in USD Million (2017–2028)
Table 59 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017–2028)
Table 60 United Kingdom Market Size of Dry Eye Disease in USD Million (2017–2028)
Table 61 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017–2028)
Table 62 Japan Market Size of Dry Eye Disease in USD Million (2017–2028)
Table 63 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017–2028)

List of Figures

Figure 1 Airway obstruction in Sleep Apnea
Figure 2 Apnea / hypopnea cycle
Figure 3 Pathological relationship between sleep apnea and cardiovascular disease
Figure 4 Risk Factors for Dry Eye Disease
Figure 5 Clinical algorithm for implementation of clinical practice guidelines.
Figure 6 Prevalent Population of Dry Eye Disease in the 7MM (2017-2028)
Figure 7 Total Adult DED Cases in 7MM (2017-2028)
Figure 8 Prevalence of Dry Eye Disease by Age Group in the United States (2017-2028)
Figure 9 Prevalence of DED in Adults in the United States (2017-2028)
Figure 10 Gender Specific Prevalence of Dry Eye Disease in the United States (2017-2028)
Figure 11 Severity-specific Prevalent Cases of Dry Eye Disease in the US (2017-2028)
Figure 12 Prevalence of Clinical Manifestation of DED in Adults in the United States (2017-2028)
Figure 13 Diagnosed Cases of Dry Eye Disease in the United States (2017-2028)
Figure 14 Prevalence of Dry Eye Disease in Germany by Age Group (2017-2028)
Figure 15 Total Prevalence of Dry Eye Disease in Adults in Germany (2017-2028)
Figure 16 Gender Specific Prevalence of Dry Eye Disease in Adults in Germany (2017-2028)
Figure 17 Severity specific prevalent cases of Dry Eye Disease in Germany (2017-2028)
Figure 18 Prevalence of Clinical Manifestation of DED in Adults in Germany (2017-2028)
Figure 19 Diagnosed Cases of Dry Eye Disease in Germany (2017-2028)
Figure 20 Prevalence of Dry Eye Disease in France by Age Group (2017-2028)
Figure 21 Total Prevalence of Dry Eye Disease in Adults in France (2017-2028)
Figure 22 Gender-specific Prevalent Cases of Dry Eye Disease in France (2017-2028)
Figure 23 Severity Specific Prevalence of Dry Eye Disease in France (2017-2028)
Figure 24 Prevalence of Clinical Manifestation of DED in Adults in France (2017-2028)
Figure 25 Diagnosed Cases of Dry Eye Disease in France (2017-2028)
Figure 26 Prevalent Cases of Dry Eye Disease By Age Group in Italy (2017-2028)
Figure 27 Total Prevalence of Dry Eye Disease in Adults in Italy (2017-2028)
Figure 28 Gender-specific Prevalence of Dry Eye Disease in Italy (2017-2028)
Figure 29 Severity specific Prevalent Cases of Dry Eye Disease in Italy (2017-2028)
Figure 30 Prevalence of Clinical Manifestation of DED in Adults in Italy (2017-2028)
Figure 31 Diagnosed Cases of Dry Eye Disease in Italy (2017-2028)
Figure 32 Prevalence of Dry Eye Disease by Age Group in Spain (2017-2028)
Figure 33 Total Prevalence of Dry Eye Disease in Adults in Spain (2017-2028)
Figure 34 Gender Specific Prevalence of Dry Eye Disease in Spain (2017-2028)
Figure 35 Severity specific Prevalent Cases of Dry Eye Disease in Spain (2017-2028)
Figure 36 Prevalence of Clinical Manifestation of DED in Adults in Spain (2017-2028)
Figure 37 Diagnosed Cases of Dry Eye Disease in Spain (2017-2028)
Figure 38 Prevalent Cases of Dry Eye Disease in the United Kingdom (2017-2028)
Figure 39 Total Prevalence of Dry Eye Disease in Adults the United Kingdom (2017-2028)
Figure 40 Gender Specific Prevalence of DED in the United Kingdom (2017-2028)
Figure 41 Severity specific Prevalent Cases of Dry Eye Disease in the UK (2017-2028)
Figure 42 Prevalence of Clinical Manifestation of DED in Adults in the UK (2017-2028)
Figure 43 Diagnosed Cases of Dry Eye Disease in the United Kingdom (2017-2028)
Figure 44 Age Group Specific Prevalence of Dry Eye Disease in Japan (2017-2028)
Figure 45 Total Prevalence of Dry Eye Disease in Adults Japan (2017-2028)
Figure 46 Gender Specific Prevalence of Dry Eye Disease in Japan (2017-2028)
Figure 47 Severity specific Prevalent Cases of Dry Eye Disease in Japan (2017-2028)
Figure 48 Prevalence of Clinical Manifestation of DED in Adults in Japan (2017-2028)
Figure 49 Diagnosed Cases of Dry Eye Disease in Japan (2017-2028)
Figure 50 Unmet Needs for Dry Eye Disease
Figure 51 7 Major Market Size of Dry Eye Disease in USD Million (2017-2028)
Figure 52 Therapy Based Market Size of DED in 7MM in USD Million (2017-2028)
Figure 53 Market Size of Dry Eye Disease in the United States, USD Millions (2017-2028)
Figure 54 Therapy Based Market Size of DED in USD Million (2017-2028)
Figure 55 Market Size of Dry Eye Disease in Germany, USD Millions (2017-2028)
Figure 56 Therapy Based Market Size of DED in USD Million (2017-2028)
Figure 57 Market Size of Dry Eye Disease in France USD Millions (2017-2028)
Figure 58 Therapy Based Market Size of DED in USD Million (2017-2028)
Figure 59 Market Size of Dry Eye Disease in Italy, USD Millions (2017-2028)
Figure 60 Therapy Based Market Size of DED in USD Million (2017-2028)
Figure 61 Market Size of Dry Eye Disease in Spain, USD Millions (2017-2028)
Figure 62 Therapy Based Market Size of DED in USD Million (2017-2028)
Figure 63 Market Size of Dry Eye Disease in the UK, USD Millions (2017-2028)
Figure 64 Therapy Based Market Size of DED in USD Million (2017-2028)
Figure 65 Market Size of Dry Eye Disease in the UK, USD Millions (2017-2028)
Figure 66 Therapy Based Market Size of DED in USD Million (2017-2028)
Figure 67 Market Drivers
Figure 68 Market Barriers

Companies Mentioned

A selection of companies mentioned in this report includes:

Santen Pharmaceutical
Mitotech pharma
ReGen Tree
HanAll BioPharma
Mimetogen Pharmaceuticals
Ocugen
Kala Pharmaceuticals
Novaliq
Sun Pharma
Sylentis, S.A.
Aldeyra Therapeutics
Novartis

Table of Contents

Companies Mentioned

Related Topics

Related Reports

Global Dry Eye Treatment Devices Market Size, Share & Industry Trends Analysis Report by Technology, End-user, Regional Outlook and Forecast, 2022-2028

Ophthalmic Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Age-related Macular Degeneration (AMD) - Market Insight, Epidemiology And Market Forecast - 2032

Global Dry Eye Syndrome Treatment Market Size, Share & Industry Trends Analysis Report by Type, Drug, Dosage, Distribution Channel, Sales Channel, Product, Regional Outlook and Forecast, 2022-2028

Dry Eye Syndrome Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028